Board Committees

Audit Committee

The Audit Committee is appointed by the Board and consists of Heidi Hunter (Chairman), Jacob Gunterberg and Yasir Al-Wakeel.

The main tasks of the Audit Committee are as follows:

monitor the company’s financial reporting,
monitor the effectiveness of the company’s internal control, internal audit and risk management
keep informed of the audit of the annual accounts and the consolidated accounts,
review and monitor the auditor’s impartiality and independence and in this case pay special attention to whether the auditor provides the company with services other than audit services, and
assist in the preparation of proposals for the general meeting’s election of auditor.

Remuneration Committee

The Remuneration Committee shall be appointed by the Board and consists of Hans Schikan (chairman), Ann Barbier and Jacob Gunterberg.

The Remuneration Committee’s main tasks are the following:

prepare the board of director’s decisions on issues concerning remuneration principles, remunerations and other terms of employment for the executive management,
monitor and evaluate programs for variable remuneration, both ongoing and such that have ended during the year, for the executive management, and
monitor and evaluate the application of the guidelines for remuneration to the executive management established by the annual general meeting, as well as the current remuneration structures and remuneration levels in the Company.

Science Committee

The Science Committee shall be appointed by the Board and consists of Elisabeth Björk (chairman), Ann Barbier and Peter Guenter.

The primary duties and responsibilities of the Science Committee are:

To review and discuss the preclinical and clinical product portfolio of the Company, including the commercial attractiveness and the ranking thereof,
To review and discuss the Company’s R&D strategy and to review science and technology trends that the Company believes are of significant importance,
To provide strategic advice and make recommendations to the ongoing R&D programs of the Company,
To review the (quality of) the R&D capacity of the Company and the organization thereof, including the product development process, and
To review and discuss the Company’s intellectual property strategies.